Printer Friendly

Tissera reports finding optimal time to procure embryonic tissue that will grow into organs.

Tissera, Inc., Tel Aviv, Israel, announced it has identified the optimal gestational "window" to procure and dissect embryonic tissue in pigs to differentiate between teratoma (tumor which is made up of a heterogeneous mixture of tissues, as of bone, cartilage and muscle) producing tissue as opposed to precursor tissue which leads to heart, liver and pancreas development without teratoma. The specific anatomical sites which serve as tissue precursors for different organs exhibit different "windows."

The company calls the breakthrough is a significant milestone in its ability to eventually develop and grow organs for transplantation in humans. "Our ability to identify exactly when a cell is committed to developing into a specific organ enables our team to harvest precursor cells that have a predetermined destiny and control and influence their growth. It is an important stepping stone in reaching our goal to develop a reliable source of viable organs for transplantation," says Vicki Rabenou, Tissera CEO.

The company reports the scientists' identification of the precise gestational window for timely procuring future heart, liver and pancreas in pigs has significant impact on Tissera's ability to begin the next stage of research on the establishment of embryonic precursor tissues as a new source for organ transplantation.

Tissera announced on March 22 that it had completed an equity private placement with a group of individual and institutional investors representing gross proceeds to the company of $5.5 million.

Contact: Tissera Web site: www.tissera.com
COPYRIGHT 2004 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Apr 30, 2004
Words:241
Previous Article:Letter to the Editor - Transplant centers responsible for "gaming" the waiting list, not OPOs.
Next Article:Geron grants XenoTrans license for nuclear transfer technology to produce transgenic pigs.
Topics:


Related Articles
Advanced Cell Technology announces use of nuclear transfer technology for successful generation of human embryonic stem cells.
Wisconsin scientists transform embryonic stem cells into blood cells.
Alternative to Embryonic Stem Cells.
BioSpin: Why adult stem cell research successes get downplayed by the media.
The Neolib Attack on Adult Stem Cells.
Tissera scientists report reaching significant milestones in pig fetal liver transplantation.
Tissera reports encouraging results from ongoing large animal experiments of pancreatic xenotransplantation.
Stem Cells Created from Adult Skin Cells.
Progress in using xenotransplants to treat type 1 diabetes reported.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters